Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Partial agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    76 result(s) found for: Partial agonist. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-000138-33 Sponsor Protocol Number: R4461-PLD-20100 Start Date*: 2021-12-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
    Medical condition: Familial Partial Lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005493-52 Sponsor Protocol Number: AIPC060820final Start Date*: 2007-03-04
    Sponsor Name:Division K Kärnsjukhuset
    Full Title: A pilot phase II study of digitoxin for Androgen-Independent Prostate Cancer (AIPC)
    Medical condition: Androgen-Independent Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004708-51 Sponsor Protocol Number: ABR55478 Start Date*: 2015-12-17
    Sponsor Name:LUMC, VRSP
    Full Title: Facilitating Sexual Memory consolidation by a partial NMDA receptors agonist
    Medical condition: Sexual arousal disorders
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000095-26 Sponsor Protocol Number: MED-GX301-02 Start Date*: 2014-07-11
    Sponsor Name:Laboratoires Leurquin Mediolanum S.A.S.
    Full Title: A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved respon...
    Medical condition: Castration-resistant prostate cancer (patients who have achieved response to first-line docetaxel chemotherapy).
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001840-38 Sponsor Protocol Number: BET207 Start Date*: 2008-08-05
    Sponsor Name:OBEcure
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017599-26 Sponsor Protocol Number: WS508648 Start Date*: 2010-01-12
    Sponsor Name:CENTRO PER LA PREVENZIONE E CURA DEL TABAGISMO
    Full Title: EFFICACY AND SAFETY OF SMOKING CESSATION WITH VARENICLINE TARTRATE IN DIBETIC SMOKERS: A DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED, TRIAL
    Medical condition: diabetic smokers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002109-22 Sponsor Protocol Number: 02/05/Hü Start Date*: 2005-12-01
    Sponsor Name:Medical University of Vienna
    Full Title: Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure
    Medical condition: both investigated drugs are well established in the treatment of heart failure or hypertension respectively. As the investigateed Patients have this conditions according to the inclusion criteria, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023228-26 Sponsor Protocol Number: TZP-101-CL-P007 Start Date*: 2011-02-18
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastroin...
    Medical condition: post-operative ileus in subjects who have undergone partial bowel resection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054048 Postoperative ileus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023229-38 Sponsor Protocol Number: TZP-101-CL-P008 Start Date*: 2011-04-21
    Sponsor Name:Tranzyme, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastroin...
    Medical condition: post-operative ileus in subjects who have undergone partial bowel resection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022117 - Injury, poisoning and procedural complications 10054048 Postoperative ileus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) ES (Ongoing) BG (Completed) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023058-35 Sponsor Protocol Number: UZB-VUB-10-001 Start Date*: 2011-01-04
    Sponsor Name:UZ BRUSSEL
    Full Title: A Two-Stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination with Ipilimumab in Patients with Previously Treated Unresectable Stage III or IV Melanoma
    Medical condition: Previously Treated Unresectable Stage III or IV Melanoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004886-42 Sponsor Protocol Number: TRA114389 Start Date*: 2013-04-01
    Sponsor Name:University of Crete
    Full Title: Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Medical condition: Patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005249-21 Sponsor Protocol Number: 1239.3 Start Date*: 2006-02-16
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer
    Medical condition: Chemo-naive hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005255-18 Sponsor Protocol Number: 1216.19 Start Date*: 2006-07-03
    Sponsor Name:Boehringer Ingelheim UK Ltd
    Full Title: A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic...
    Medical condition: Advanced Metastatic Hormone Refractory Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024208-81 Sponsor Protocol Number: CHAMPIXASTHMA Start Date*: 2011-02-04
    Sponsor Name:Christian Westergaard
    Full Title: Smoking young asthmatics: Change of inflammation and quitting cessation rate – effect of Champix
    Medical condition: Asthma and smoking cessation.
    Disease: Version SOC Term Classification Code Term Level
    1 10003553 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003228-20 Sponsor Protocol Number: 155-CL-007 Start Date*: 2006-01-12
    Sponsor Name:Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V by August 2005)
    Full Title: A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    Medical condition: Male adults with Hormone Refractory Prostate Cancer who have progressed, as evidenced by PSA progression or progression of measurable disease, after at least 1 prior chemotherapy regimen.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003084-61 Sponsor Protocol Number: CLEE011A2301 Start Date*: 2014-01-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast ...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) NL (Completed) HU (Completed) FI (Completed) IE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000367-98 Sponsor Protocol Number: TRA100773 Start Date*: 2005-02-11
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin recep...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) EE (Completed) LV (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001485-29 Sponsor Protocol Number: G1T38-02 Start Date*: 2017-03-21
    Sponsor Name:G1 Therapeutics, Inc
    Full Title: Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Bre...
    Medical condition: Hormone Receptor-Positive, HER2 Negative Metastatic Breast Cancer after Endocrine Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003839-38 Sponsor Protocol Number: BAY1067197/15128 Start Date*: 2017-03-09
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with reduced ejection fraction (LVEF equal or below 35%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023382-22 Sponsor Protocol Number: 9521-CL-0002 Start Date*: 2011-02-21
    Sponsor Name:Astellas Pharma Europe B.V. (APEB)
    Full Title: Phase I/II, multi-center, open label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASP9521 in patients with metastatic castrate-resistant p...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 00:27:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA